Beta-cell function in hypopituitary adults before and during growth hormone treatment.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Hypopituitary patients were aged 19-67 years and had a body mass index of 27.7 (18.0-41.1) kg/m2.

They were receiving replacement thyroxine, adrenal steroids and sex hormones and they were growth hormone deficient.

Who Took Part

According to the abstract, 40 adults were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The adults were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

Some adults received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

Fasting insulin, intact proinsulin and 32-33 split proinsulin were measured by two-site immunoradiometric assays. 2.

What Was Measured

Topics PubMed links to this paper include Case-Control Studies, Glucose Tolerance Test, Growth Hormone, Hypopituitarism, Insulin, Islets of Langerhans and Proinsulin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 40 adults.

The publication is from 1995 (Clinical science (London, England : 1979)), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.